Featured content
From R&D to QC: building a single analytical strategy for cell and gene therapies
2026-07-01T13:30:00+01:00Contributor Carrie Maynard and Dr Veronica Fowler
From early research to quality control, maintaining analytical continuity is no easy task. Could a single sequencing workflow help simplify analytical assessment?
Antibody recycling, FcRn and the next generation of biologics
2026-07-01T06:30:00+01:00By Dr Veronique Baron
One receptor can protect antibodies from degradation, extend their half-life and become a drug target itself. Explore the science behind FcRn and how researchers measure its function.
The global push to reduce animal testing in drug development
2026-06-29T06:49:00+01:00Contributor Laura Alvarez, By Drug Target Review
Non-animal methods are already used throughout early drug discovery, yet animal testing continues to dominate regulatory safety assessment. Recent initiatives suggest change is coming, but significant scientific and practical challenges remain.
Drug development has changed. Bioanalysis is changing with it
2026-06-24T07:00:00+01:00By Dr Abdul Basit Shaikh
As drug developers pursue increasingly complex therapies, traditional bioanalytical approaches are being put to the test. How is the field adapting to meet these new demands?
News
European initiative aims to bring molecular dynamics into mainstream drug discovery
2026-06-18T13:00:00+01:00By Drug Target Review
What if the vast amounts of data generated by molecular dynamics simulations could be routinely shared and reused? A new €10 million European initiative aims to do just that, helping researchers gain a deeper understanding of protein behaviour and drug-target interactions.
bit.bio launches iPSC-derived cell culture media kits to democratise human cell research
2026-07-06T12:00:00+01:00By Drug Target Review
Cambridge-based cell programming company bit.bio has introduced two new media kits for its iPSC-derived ioGlutamatergic Neurons and ioMicroglia, reducing media preparation costs by around 18-fold and simplifying workflows to widen access to human-relevant research models.
XL20 drug candidate shields motor neurons from ALS-linked TDP-43 damage
2026-07-06T09:00:00+01:00By Drug Target Review
A newly identified experimental compound, XL20, has demonstrated neuroprotective effects in mouse models and human motor neurons by targeting a conserved disease-linked region of TDP-43, a protein central to ALS pathology.
Dual antibody cocktail offers complete Nipah virus protection
2026-07-03T12:00:00+01:00By Drug Target Review
Researchers at Mount Sinai have developed the first fully human monoclonal antibody cocktail to provide complete protection against Nipah and Hendra viruses in preclinical models, offering a potential blueprint for treating high-consequence zoonotic pathogens with no approved therapies.
Opinion and interviews
The global push to reduce animal testing in drug development
2026-06-29T06:49:00+01:00Contributor Laura Alvarez, By Drug Target Review
Non-animal methods are already used throughout early drug discovery, yet animal testing continues to dominate regulatory safety assessment. Recent initiatives suggest change is coming, but significant scientific and practical challenges remain.
- Previous
- Next
Physics-based modelling offers a new way to study drug targets
2026-03-26T14:15:00+00:00
From scientist to bioinformatician: how AI coding tools dissolved the activation energy barrier
2026-03-19T09:00:00+00:00
How self-driving labs are changing drug development
2026-03-09T09:00:00+00:00
Why PDE4B matters in the search for better IPF and PPF therapies
2026-02-27T09:05:00+00:00
AI in drug discovery: predictions for 2026
2026-02-16T09:00:00+00:00
Making science run at the speed of thought: the reality of AI in drug discovery – Part 2
2025-11-25T09:01:00+00:00
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs
- Receive updates and recommendations tailored to your research interests
On-demand Webinars
- Previous
- Next
Where NAMs stand in early drug discovery: an expert discussion
2026-06-24T13:00:002026-06-24T13:00:002026-06-24T14:00:00Sponsored by HUB Organoids
Manufacturing the Future: from N=1 personalised CRISPR therapy to scalable precision genomic medicine
2026-06-02T15:00:002026-06-02T15:00:002026-06-02T16:00:00Sponsored by Danaher Life Sciences
From expert task to lab routine – Membrane protein purification and analysis simplified
2026-06-30T14:00:002026-06-30T14:00:002026-06-30T15:00:00Sponsored by Analytik Jena GmbH + Co. KG
What it takes to automate high-content imaging at scale
2026-03-25T15:00:002026-03-25T15:00:002026-03-25T16:00:00Sponsored by Yokogawa
The truth about AI in drug discovery: what the experts really think
2026-03-11T14:00:002026-03-11T14:00:00Sponsored by Merck
Can One Peptide Change Pain Research? Meet the Tool Transforming Drug Discovery
2025-11-19T16:00:002025-11-19T16:00:00
Overcoming Affinity and Expression Bottlenecks in TCR Discovery
2025-10-22T14:00:002025-10-22T14:00:00Sponsored by Wuxi Biologics
Innovating Obesity Drug Discovery: Trends, Challenges, and Translational Strategies
2025-10-08T14:00:002025-10-08T14:00:00Sponsored by Eurofins Discovery
Early De-Risking: In Vitro Safety Strategies for Pre-IND Success
2025-09-24T14:00:002025-09-24T14:00:00Sponsored by Eurofins Discovery